Clinical Trials | January 04, 2026
FDA nod to first new motion sickness drug in 40 years
The approval is supported by data from three pivotal clinical trials
The approval is supported by data from three pivotal clinical trials
Elanco expects Befrena to launch in the US in the first half of 2026
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
Once finalized, cough syrups will no longer be available for over-the-counter sale
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Subscribe To Our Newsletter & Stay Updated
